THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN – 2689-1026)
VOLUME 06 ISSUE12

PUBLISHED DATE: - 11-12-2024
DOI: - https://doi.org/10.37547/TAJMSPR/Volume06Issue12-06 **PAGE NO.: - 36-53**

RESEARCH ARTICLE **Open Access**

CANCER DRUG SENSITIVITY THROUGH GENOMIC DATA: INTEGRATING INSIGHTS FOR PERSONALIZED MEDICINE IN THE USA HEALTHCARE SYSTEM

Ekramul Hasan
College of Engineering and Technology, Westcliff University, Irvine, California, USA

Md Musa Haque
School of Business, International American University, Los Angeles, California, USA

Shah Foysal Hossain
School of IT, Washington University of Science and Technology, Alexandria, Virginia, USA

Md Al Amin
School of Business, International American University, Los Angeles, California, USA

Shahriar Ahmed
School of Business, International American University, Los Angeles, California, USA

Md Azharul Islam
College of Business, Westcliff University, Irvine, California, USA

Irin Akter Liza
College of Graduate and Professional Studies (CGPS), Trine University, Detroit, Michigan, USA

Sarmin Akter
School of Business, International American University, Los Angeles, California, USA

Corresponding Author: Ekramul Hasan

THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN – 2689-1026)
VOLUME 06 ISSUE12

Abstract

Despite the significant progress in cancer genomics in America, there is still a noteworthy gap regarding genomic markers that predict drug sensitivity which presents a major obstacle to personalized oncology care. Tumors This research project aims to identify a set of genetic variations or mutations that influence the individual response of a cancer patient to certain drugs. This study also aims to develop machine learning models that can analyze a patient's genomic data to predict their likely response to different therapies. This study utilized the Genomic of Drug Sensitivity in Cancer (GDSC). The GDSC dataset is a very valued resource in therapeutic biomarker discovery in cancer research. This dataset combined drug response data with genomic profiles of cancer cell lines, enabling investigations into the relationship between genetic features and drug sensitivity. The main task associated with this dataset was to predict drug sensitivity, measured as IC50 values, from genomic features of cancer cell lines. Several accredited and proven Machine Learning algorithms were utilized in the study, particularly, Linear Regression, Ridge Regression, and SGD Regression. The most important regression model evaluation metrics deployed in a drug sensitivity prediction included the Mean Squared Error- MSE, Root Mean Squared Error- RMSE, and Mean Absolute Error- MAE. The Ridge Regression model outperformed the Linear Regression and the SGD algorithm, particularly, the Ridge Regression model captured excellently the hidden trends in the data much better compared to the other two models. Predictive analytics can significantly enhance clinical decision-making in the USA by providing health professionals with data-driven insights into the best available treatment options. As patient complexity and treatment options continue to grow, such models will help clinicians choose the most appropriate interventions for individual patients, informed by historical data on their disease course and other individual patient factors, including genetic profiling and comorbid status.

Keywords Genomic markers; Oncology; Drug sensitivity; Predictive models; Personalized medicine; Cancer treatment; Precision Medicine; USA healthcare system.

INTRODUCTION

Background

Fawaz et al. (2023), reported that personalized medicine in oncology portrays a paradigm shift from a one-size-fits-all dimension to one that considers personal genetic variability in drug response in the US. Recent advances in next-generation sequencing and bioinformatics have been the gateway to understanding genetic mutations, copy number variations, and expression changes that determine tumor behavior and therapeutic response. Alam et al. (2023), indicated that precision medicine offers enhanced efficacy, reduced toxicity, and improved survival rates by tailoring treatment plans to the unique molecular profile of the patient. In the USA, where cancer is one of the leading causes of morbidity and mortality, such advances could go a long way in easing the burden on the healthcare system.

Bhomik et al. (2024), asserted that while these promises have been made, the prediction of drug sensitivity in cancer remains a formidable challenge. Tumors are highly heterogeneous, not only between different patients but also within the same patient, both intertumoral and intratumoral heterogeneity. The drug response is further complicated because of the complex interplay among genomic alterations, tumor microenvironment, and immune system. Many current predictive models have small datasets, capture less real-world complexity, and lack generalizability across diverse populations. Moreover, the US healthcare system faces the additional challenge of integrating these genomic insights into routine clinical practice in the presence of disparities in access and affordability (Dutta et al., 2024).

Genomic data have illuminated the key pathways

to drug sensitivity and resistance. For instance, in the treatment of NSCLC, mutations in the EGFR gene predict the response to tyrosine kinase inhibitors, while BRCA1/2 mutations confer sensitivity to PARP inhibitors in breast and ovarian cancers (Chafai et al. 2024). These markers will guide drug selection and point to mechanisms of resistance so that second-line therapies may be devised. Bortty et al. (2023), argued that with the ever-increasing use of whole-genome sequencing of tumors, transcriptomic and even epigenetic data, these advances certainly fuel the cataloging of even more actionable biomarkers that impress centrality on solitary genomic material data in the precision of oncology.

Problem Statement

Hossain et al. (2023), posited that despite the considerable progress in cancer genomics in the USA, there is still a noteworthy gap regarding genomic markers that predict drug sensitivity which presents a major obstacle to personalized oncology care. Tumors are heterogeneous both at genetic and phenotypic levels; this gives rise to their different responses to the same therapeutic agents among patients. Islam et al. (2023), stated that although some biomarkers, like EGFR mutations in lung cancer and BRCA mutations in breast and ovarian cancers, have been highly useful for target therapy, the genomic landscape that dictates drug sensitivity is much more complex and is still poorly characterized in many malignancies. Moreover, current research often covers common cancers and lacks comprehensive representation of rare cancers and diverse patient populations, including ethnic minorities, which could limit generalization. Even then, the USA health system uses many resources, but with standardization, high costs of technology, and lack of accessibility of precision medicine tools in various locations, translation of these genomic insights fully into clinical practice remains incompletely achieved (Dutta et al., 2023). Overcoming such gaps will be pivotal toward the optimization of treatment outcomes as well as furthering science regarding the field of precision oncology.

Research Questions

RQ1: What genomic markers are associated with drug sensitivity in cancer?

This research question aims to identify a set of genetic variations or mutations that influence the individual response of a cancer patient to certain drugs. In doing so, the research question will provide some significant predictions regarding who would benefit from a specific treatment and who would have undesirable side effects.

RQ2: How can predictive models be developed to guide personalized treatment plans?

To develop machine learning models that can analyze a patient's genomic data to predict their likely response to different therapies. These models could help clinicians select the most effective treatment options for each patient, optimizing their chances of successful treatment.

RQ3: How can integrating genomic data improve patient outcomes in oncology?

The objective of this research question is to get the general ramifications of the use of genomic information in clinical decision-making in oncology. This may be based on a review of the clinical utility of genomic testing, a review of the cost-effectiveness of personalized medicine, and/or a review of the potential barriers to the widespread adoption of genomic-based treatments.

Significance of the Study

This research project is highly significant because it contributes to advancing precision medicine in

oncology, particularly within the US healthcare system. This study intends to identify and characterize genomic markers associated with drug sensitivity, refining treatment selection to allow for more effective and personalized cancer therapies. Such an advancement may reduce the trial-and-error approach in treatments, thereby reducing toxicities related to treatment and improving outcomes. Moreover, in oncology, there will be a great need to translate these genomic data into predictive models that could allow more tailored interventions for a wide range of populations. Importantly, these might lead to healthcare policies that include calls for broader access to genomic testing and equal access to all levels of precision medicine technologies. The integration into such a resource-intensive, varied system as that of the USA will enhance clinical outcomes and reduce costs through avoidance of ineffective treatments, thus changing the standard of care in oncology.

LITERATURE REVIEW

Overview of Cancer Genomics and Precision Medicine

As per Joshi et al. (2024), cancer genomics has revolutionized oncology, where the genetic causes of development, tumor progressions, and response to pharmacology are all widely known. Advances in high-throughput sequencing technologies, such as next-generation sequencing, enable one to readily identify somatic mutations, copy number variations, epigenetic changes, and transcriptional alterations forced by oncogenesis. These opened new avenues to precision medicine, where therapies were curtailed according to the molecular profile of individual tumors. Rahman et al. (2023), postulated that precision medicine holds tremendous promise for treatment efficacy with fewer side effects by targeting genetic alterations rather than the classical broadly cytotoxic therapies. Spectacular successes include therapies directed against the HER2 protein in breast cancer, ALK rearrangements in lung cancer, and BRAF mutations in melanoma, each demonstrating the potential of genomically informed interventions to transform clinical outcomes.

Precision medicine is increasingly becoming the focus of cancer care in the US and is supported by initiatives such as the Precision Medicine Initiative of the NCI. However, there are several challenges to its implementation in the diverse and complex US healthcare system. While comprehensive genomic testing and targeted therapies are offered in academic and large cancer centers, access to these resources remains limited for many patients, particularly those in rural or underserved communities (Restrepo et al., 2023). The high costs of both genomic testing and targeted therapies, along with disparities in insurance coverage, further exacerbate disparities in precision oncology. Furthermore, the US healthcare system must address several logistic and ethical challenges associated with integrating large-scale genomic data into clinical workflows in a way that this transformative approach benefits all patients equitably (Hider et al., 2024).

Drug Sensitivity and Genomic Markers

Research regarding genomic markers has significantly enhanced the knowledge of drug sensitivity and resistance in diverse cancers. Expression profiles, gene amplifications, and certain mutations correlate strongly with response to select therapies. For instance, mutations in the EGFR gene predict sensitivity to tyrosine kinase inhibitors, such as erlotinib, in non-small cell lung cancer (Obijuru et al., 2023). HER2 gene changes dictate treatment decisions for trastuzumab in HER2-positive breast cancer, and BRCA1/2 mutation status predicts response to PARP

inhibitors like olaparib in both breast and ovarian cancers (Kang et al., 2023). Furthermore, other genomic markers like tumor mutational burden and microsatellite instability have evolved into predictors of response with the advent of immune checkpoint inhibitors, thus expanding this breadth of precision medicine applications.

According to Tong et al. (2023), despite these advances, most genomic markers remain incompletely understood or poorly validated in diverse patient populations. Most studies have focused on common cancer types, whereas genomic markers of rare cancers or subsets of resistant tumors are underexplored. Moreover, tumor heterogeneity further complicates the quest for universal biomarkers; different regions of a single tumor may harbor distinct genetic profiles that could impact drug sensitivity. Integration of multi-omics data, referring to genomics, transcriptomics, proteomics, and epigenomics combined, has the potential to resolve some of these challenges; clinically, this is still scant.

Machine Learning in Cancer Genomics

Machine learning has become a powerful tool to analyze complex genomic data and predict drug sensitivity in cancers. ML algorithms-actually supervised, unsupervised, and reinforcement learning detect pattern recognition and relations among huge data that may be indistinct from conventional statistical analysis (Sadee et al., 2023). Such techniques are therefore especially effective for the integration of multi-omics data; these will enable the creation of predictive models considering both genetic and epigenetic contributions with their environmental interaction. One of the popular strategies includes the use of supervised learning algorithms such as support vector machines and random forests that predict, with the use of genomic features, the response of patients to particular drugs. The deep learning models, including CNNs and RNNs, have also shown great promise in uncovering novel biomarkers by analyzing high-dimensional data, such as whole-genome sequencing and transcriptomic datasets. Similarly, incorporating ensemble learning, with some different algorithms predicting jointly, helps in enhancing accuracy within sensitive drug prediction (Wang & Wang, 2023).

Hider et al., (2023), argued that applications of Machine Learning in cancer genomics are not immune from challenges: most require a great amount of training data, and the generalization to various populations of patients normally remains narrow. Besides, sometimes the algorithms, particularly deep learning models, tend to lack interpretability; this also further complicates their adoption in clinical settings. To this end, the focus has recently been shifted by researchers toward developing explainable AI models that integrate an external validation dataset for assuredly robust and actionable prediction.

Challenges and Limitations

The integration of genomic data in personalized medicine has immense promise combined with considerable challenges and many limitations. One major hindrance is the high cost of testing and sequencing which prevents many patients from reaching these facilities (Dutta et al., 2024). The cost of sequencing has fallen dramatically during recent years, but comprehensive genomic profiling remains especially considering associated costs related to data analysis, interpretation, and clinical integration (Hossain et al., 2023).

The second challenge relates to data quality and availability. There is usually a big difference in completeness, accuracy, and the way different genomic datasets are represented, with most studies overrepresented by patients from certain

demographic backgrounds (Islam et al., 2024). This underrepresentation of ethnic minorities and underserved populations results in disparities in the development and validation of predictive models, limiting their applicability across the diverse patient population in the USA (Al Amin et al., 2024).

Besides, it has logistic difficulties in integrating the genomic data into routine clinical practice. Oncologists lack training or resources to interpret complex genomic findings, and gaps in communication between researchers, clinicians, and patients do occur (Al Amin et al., 2023). The amount of genomic data generated is so immense that robust infrastructure in terms of storage, processing, and sharing is often lacking in many small health settings.

Furthermore, there are ethical and regulatory barriers to progress. There is much concern over the use of genomic data, such as patient privacy and data security and the acquisition of informed consent, given the increasingly shared nature of these datasets between institutions and the ever-growing research in which they are used (Acanda et al., 2023). Regulatory frameworks need to be balanced between a need for innovation and protection of patients' rights to ensure that genomic information is used responsibly and equitably.

Data Collection and Preprocessing

Data Sources

This study utilized the Genomic of Drug Sensitivity in Cancer (GDSC). The GDSC dataset is a very valued resource in therapeutic biomarker discovery in cancer research. This dataset combined drug response data with genomic profiles of cancer cell lines, enabling investigations into the relationship between genetic features and drug sensitivity(Alipour et al, 2024). The main task associated with this dataset was to predict drug sensitivity, measured as IC50 values, from genomic features of cancer cell lines. It includes regression tasks for the prediction of exact IC50 values or classification tasks that categorize cell lines as sensitive or resistant to specific drugs. The dataset enables the identification of genomic markers that correlate with drug response.

Data Preprocessing

Firstly, the provided Python code snippet began by handling missing values, employing different strategies based on data types: mean imputation for numeric columns and most frequent value imputation for categorical columns. Secondly, one Hot encoded categorical variable, where the binary columns were label encoded and the columns having more than two categories are one-hot encoded. Thirdly, if numeric features existed, it did scale with a standard scaler on the features. These preprocessing steps ensured that the data would be ready for training of the model, solving different problems such as missing data, inconsistent data types, and imbalanced feature scales that can seriously affect the performance of the model.

THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN – 2689-1026)
VOLUME 06 ISSUE12

Exploratory Data Analysis (EDA)



Figure 1: Displays Boxplot of LN_IC50 by Top Drug Names

The Box plot of LN_IC50 showcases the distribution and dispersal of drug potencies for the top-ten-ranked drug names in which the central tendencies of drugs' efficiency corresponding to a median LN_ IC50 include higher medians and thereby enhance in comparison with others including "Dasatinib and "Sunitinib," whereas "Ubenimex" and "XG-132.". The outliers in "Acelarin" and "Ubenimex" indicate great variability in the responses, while the interquartile ranges show the range of drug responses. Overall, this chart visualizes the comparative efficacy of these drugs based on their IC50 values.



Figure 2: Portrays Top 15 Putative Targets Count

This graph shows the frequency count for the top 15 putative targets in the biological study. "PARP1" and "PARP2" are in the leads, with over 4,500 counts each, meaning that these proteins are among the most therapeutically targeted. This is followed by "MEK1," "MEK2," and "TOP2," all with

respectable counts, suggesting the same kind of relevance as described earlier in drug development or mechanisms of disease. That means the targets "EGFR," "TNS1-TNS2," and "AKT" are remarkable, having more than 2,000 counts, thus important in many biological pathways. The gradual decline to the lower end with "Microtubule-stabilizing agent" and "B804" underlines a decreasing interest or relevance of these latter targets, thus emphasizing the focus on the top few in future research or therapeutic strategies.



Figure 3: Showcases the Pair plot of Selected Features

The pairplot visualizes the relationships between selected features: LN_IC50, AUC, RMSE, and Z_SCORE, showing their distributions and correlations. In the diagonal plots of this figure, the density distributions for each feature are shown; from these, it is obvious that LN_IC50 and RMSE are skewed, while AUC and Z_SCORE are closer to normal distributions. In the scatter plots, there is a well-marked trend between LN_IC50 and AUC, possibly inversely related because the higher the value that LN_IC50 takes up, the lower the value in AUC. Another kind of pattern with RMSE stands out for both LN_IC50 and AUC-such that if the improvement in the model's prediction, which is reflected through RMSE, improves, that is where the respective value of LN_IC50 and AUC changes enormously. Overall, this pairplot shows the complexity and interdependencies of these features well, which might be useful for further analysis and model refinement.

METHODOLOGY

Feature Engineering and Selection

Feature engineering is one of the most important steps in making useful predictive models from

genomics data. In cancer genomics, raw data consisted of high-dimensional genomic datasets constituted by DNA sequencing, RNA expression profiles, and epigenetic markers. Such datasets require extraction techniques that involve dimensionality reduction, statistical summarization, and biological annotation to generate meaningful features. These can provide actionable features related to drug response, for example, the identification of somatic mutations including SNVs and CNVs. In the same way, transcriptomic data can be processed to quantify differential gene expression levels, thus underlining key pathways associated with sensitivity or resistance to therapies. Other approaches involve the calculation of composite features, either by summarizing the information of interest into a particular variable, such as tumor mutation burden count summarizing the total number of mutations gene set enrichment scores, which evaluate the functional status of a given biological pathway.

Feature selection is important and was done in a manner that enhanced model interpretability with less overfitting, besides being computationally more efficient. In cancer genomics, this technique was mostly guided by the biological relevance and statistical significance of the features. Some techniques used include univariate feature selection, which is based on statistical tests ranking features individually concerning the target variable. Alternatively, other embedded methods, such as feature importance scores derived from tree-based models like random forests, directly embed feature selection in modeling. Besides statistical methods, biological knowledge plays a major role in feature selection. For example, mutations in well-characterized oncogenes and tumor suppressor genes, such as TP53, EGFR, and BRCA1/2, are prioritized because of their established links to cancer phenotypes and drug response. Cross-validation techniques are often employed to validate the stability and predictive power of selected features across different subsets of the data. Ultimately, the goal is to identify a subset of features that balances predictive accuracy with biological plausibility and generalizability.

Model Selection and Justification

Several accredited and proven Machine Learning algorithms were utilized in the study, particularly, Linear Regression, Ridge Regression, and SGD Regression. Linear regression models, such as OLS, introduce a simple way of weighing relationships between genomic features about drug response. An extension of linear regression, introducing regularization, is the renowned Ridge Regression, which is remarkably well adapted for high-dimensional data: the regularization penalizes large coefficients to prevent over-fitting. Another popular approach is the stochastic gradient descent regression model, which efficiently processes big datasets by iterative updating of model parameters to minimize prediction error. The choice of model depended on the nature of the data and specific prediction goals. Linear regression and ridge regression are applicable for moderately featured datasets where there is a linear relation between the inputs and outputs. Given that ridge regression can handle multicollinearity, it is very useful in genomics, where many features are interdependent. For large-scale genomic datasets, SGD regression is computationally efficient.

Training and Testing Framework

A robust training and testing framework was needed for testing the performance of ML models. The dataset had been split randomly into two subsets: one for training, used to build the model,

and one for testing to assess its predictive accuracy. The analyst allocated 70–80% of the data for training and the rest 20–30% for testing. Stratified sampling is often done when the target variable is imbalanced to ensure that both subsets reflect the same distribution of responders and non-responders to treatment. Cross-validation provided further enhancements to the reliability of model evaluation, which involved partitioning the training data into more than one-fold. In 'k' -fold cross-validation, k subsets are included in a set, a model trained using k-1 folds where the remaining fold represents the validation, and the process is repeated k number of times for all of them, thereby making sure that every fold represents the validation set once or more times. The average estimated performance overall folds ensured a proper evaluation of the ability of a model to be generalized.

Hyperparameter Tuning

Hyperparameter tuning is one of the most important factors in maximizing the performance of ML models. This study deployed proven approaches such as grid search, random search, and Bayesian optimization. Grid search was an exhaustive search over a predefined set of hyperparameter values, considering every combination systematically. While comprehensive, this method can be computationally expensive, especially for models with many hyperparameters. Random search provided a more efficient alternative by sampling a subset of the hyperparameter combinations from the search space. This approach often found near-optimal parameters with fewer evaluations and is thus suitable for high-dimensional spaces. Bayesian optimization goes a step further by using probabilistic models to predict the performance of hyperparameter combinations, guiding the search toward promising regions of the space. Models leverage automated tools such as Sci-kit-learn's method to tune, GridSearchCV, and Hyperopt--already integrated with cross-validation during the performance evaluation. But clearly, the specific hyper-parameters related to tuning vary by mode; for example, including regularization strength in ridge, the learning rate in stochastic gradient descent, and two in random forests. Their most proper tuning will make every model achieve a balance beyond underfitting and inclusive of overfitting capabilities concerning performance generally.

Performance Evaluation Metrics

Model evaluation is an important step to ensure that the ML model generalizes well to new, unseen data and performs well. In cancer genomics, it would involve a prediction of drug sensitivity from genomic data; hence, model evaluation helps to provide the extent to which a model can predict the outcomes of treatment. Various metrics are implemented to evaluate the performance of the model, each considering different aspects of prediction accuracy. The most important regression model evaluation metrics deployed in a drug sensitivity prediction included the Mean Squared Error- MSE, Root Mean Squared Error-RMSE, and Mean Absolute Error- MAE.

RESULTS

Genomic Marker Identification



Figure 4: Visualizes the Genomic Marker Identification

As showcased above, the chart identifies the most important findings associated with biomarker detection and localization for tumor identification and renal clearance. It underlines that the limit for image detection is 1 cm^3, which will correspond to the minimum tumor volume detectable, a situation so crucial for early diagnosis. It points to an incipient tumor with 10^6 cells/ mm^3 density, with the need for timely detection associated with the management of the disease. The renal clearance section highlights that filtration of the biomarker occurs for molecules of less than 60,000 molecular weight, circulating for 10 to 20 seconds, and thus very short. Furthermore, it is underlined that a volume of 5 mL represents 1/1000th of total blood volume, and therefore a sufficient amount of data could be retrieved without significant impact on the patient. Having in mind its half-life ranging from a few minutes up to hours and its degradation course in 24 hours within the bloodstream, the question of appropriate timing is underlined to be very critical when collecting the sample for correct assessment. Overall, this information will provide important clues on the optimization of tumor detection by biomarkers and their utility in clinical practice.

Model Performance

a) Linear Regression

Table 1: Exhibits the Linear Regression Classification Report

```
Linear Regression:
Mean Squared Error (MSE): 0.013821325011252758
Root Mean Squared Error (RMSE): 0.11756413148257745
Mean Absolute Error (MAE): 0.07640898966885008
R2 Score: 0.9861777491653235
```

The table above shows the result of a linear regression, including some key performance metrics that assess the model's performance. The MSE is reported at 0.0138, which is pretty low in terms of average squared discrepancies between predicted and actual values; hence, the general performance of the model can be considered good. This is furthered by the RMSE value of about 0.1176 since this can be more interpretable because it is in the same units as the dependent variable, which is the average value of the prediction error. In addition, the MAE of 0.0746 represents the average over the absolute differences between the predictions and actual results, and this is similarly indicative of the fairly reasonable level of accuracy. Last but not least, the R^2 Score is 0.9862, indicating that the model explains about 98.62% of the variance in the dependent variable; this suggests an excellent fit. All these metrics together provide evidence that the linear regression model works extremely well to predict the outcomes using the input features.

b) Ridge Regression

Table 2: Showcases Ridge Regression Classification Report

```
Ridge Regression:
Mean Squared Error (MSE): 0.013726730924848544
Root Mean Squared Error (RMSE): 0.11716113231293279
Mean Absolute Error (MAE): 0.0758842076069195
R2 Score: 0.986272349588126
```

The Table above shows the output of Ridge regression, including some relevant performance metrics: MSE equals 0.0137, which is low, considering the average squared deviation between predicted and actual values is small, hence effective model performance. RMSE is approximately 0.1172, which, being in the same units as the dependent variable, provides an intuitive sense of the prediction error. The Mean Absolute Error has a value of 0.0759, reinforcing even the model's precision is, that the average variance from results predicted to their actual result realizations is at 0.0759. By far, it has an R^2 score of 0.9863, which infers that the model itself also explains about 98.63% in variation as depicted by the dependent variable across the model, and, to say the least, any model with these statistical inferences would be both sound enough and robust in itself also with a strong predictive power that can be deployed, always. Taken together, these metrics put up a very strong performance by any measure for the Ridge regression model in capturing the latent relationships in the data.

c) SGD Regression Model

Table 3: Illustrates the SGD Regression Model Classification Report

```
SGD Regression:
Mean Squared Error (MSE): 1.4735387065167522e+21
Root Mean Squared Error (RMSE): 38386699604.377975
Mean Absolute Error (MAE): 476514745.4004473
R2 Score: -1.4736374117168112e+21
```

The image displays the result of an SGD regression analysis including several key performance metrics. The Mean Squared Error (MSE) is extraordinarily high at around 1.475 x 1021, showing large differences between the values that are estimated and those present - which suggests that this is a bad model performance. The Root Also, the RMSE is huge, about 3.838 X 1021, meaning that the average prediction error is high and hence not easily interpretable in practical terms. Similarly, the MAE stands high at approximately 4.765 x 1021, furthering the model's inaccuracy. The R2 Score is approximately -1.473. This means that the model is generally worse than a simple mean-based prediction, clearly an indication of poor fit to the data. In general, these metrics reveal that the SGD regression model is not capturing the underlying relationships in the dataset effectively.

Comparison of Model Performance



Figure 5: Depicts Comparison of Model Performance

Above is the bar chart of the comparison of performance between three regression models: Linear Regression, Ridge Regression, and SGD Regression. These models are all based on Mean Absolute Error or MAE. The chart highlights the highest MAE corresponds to the SGD Regression model, which is close to 5 x 10 while others have a very minimal prediction error. Conversely, Linear and Ridge Regression models far outperform the SGD algorithm, with the Ridge Regression best at 0.08 MAE, which is a very low average absolute error in predictions. The large difference in MAE reflects the fact that the Ridge Regression model captured excellently the hidden trends in the data much better compared to the other two models, with the obvious underperformance of the SGD Regression model.

Predictive Insights

Predictive insights from models that assess drug sensitivity could potentially enhance personalized medicine and treatment planning for a particular patient. These models can predict how a certain patient is likely to react against a particular treatment regimen by using historical data on the various responses of patients to different drugs. For instance, in oncology, machine learning algorithms can be trained on genomic data to identify mutations influencing drug efficacy. If a

model indicates a patient with breast cancer is most likely to respond well to a certain type of HER2-targeted therapy based on their genetic profile, then the clinicians may prioritize that treatment and could improve outcomes. This predictive capability not only helps in choosing the most effective drugs but also minimizes the risk of adverse reactions by avoiding ineffective therapies.

Case studies further illustrate how great the impact of these predictive models is on treatment planning. In one such empirical study by Joshi et al. (2023), investigating metastatic melanoma patients, for example, a predictive model was developed that combined clinical, genomic, and pharmacological data to predict responses to immunotherapy. The results showed that patients predicted to be responders exhibited significantly improved survival rates compared to those predicted to be non-responders. Another good example is in the treatment of CML, where models integrating genetic mutations have guided the selection of tyrosine kinase inhibitors, thus optimizing treatment strategies for improved patient outcomes. These practical applications indicate the transformation that can be realized with predictive insights in personalizing drug therapy from one-size-fits-all to more tailored and effective treatment strategies.

DISCUSSION

Clinical Implications

Predictive analytics can significantly enhance clinical decision-making in the USA by providing health professionals with data-driven insights into the best available treatment options. As patient complexity and treatment options continue to grow, such models will help clinicians choose the most appropriate interventions for individual patients, informed by historical data on their disease course and other individual patient factors, including genetic profiling and comorbid status. It might go into predicting, with its models in oncology, whether specific genomic alterations will show that certain patients will benefit from particularly targeted therapies; it, therefore, streamlines the process of treatment selection and, finally, improves patient outcomes. They could be useful for risk stratification to help clinicians optimize resource utilization and tailor follow-up strategies in the context of the projected course of the disease.

To efficiently consolidate machine learning algorithms into clinical workflows, several recommendations can be made. First, collaboration among data scientists, healthcare providers, and clinical decision-makers should be built so that models can be developed with deep insight into clinical needs and workflows. Training programs need to be instituted for healthcare professionals to provide them with the necessary competencies to interpret model outputs and integrate them into their decision-making processes. It will be important, secondly, to advance development in user-friendly interfaces that embed the results of predictive analytics within electronic health records and thus allow providers to access such insights in real-time during patient consults. Lastly, performance evaluation of these models should be conducted constantly for updates to make them current and relevant as new data emerges.

Integration into the USA Healthcare System

Predictive models in healthcare institutions in the US should be implemented in a very strategic way, considering all the technical and operational concerns. For this, healthcare institutions must make the required investment in infrastructure that includes robust data management systems to process large volumes of patient data and integrate

machine learning algorithms with existing EHR systems. Even collaboration with technology vendors can, in turn, help and engage resources in developing appropriate solutions suited for various healthcare settings, which can be located within general practice, outpatient settings, hospitals, or specialist treatment clinics.

The potential benefits of consolidating AI-driven predictive algorithms into clinical workflows are significant. Better and improved predictions about treatment efficacy, as well as adverse reactions related to improved patient outcomes, are thus assured for the clinicians. This personalized approach not only offers quality care but also saves treatment costs by reducing hit-and-trial approaches toward therapy. For instance, by identifying prospectively which patients will benefit from certain therapies, healthcare providers can avoid therapies and hospitalizations that are not necessary, thus ultimately using healthcare resources more efficiently.

Challenges and Limitations

Notwithstanding, provided the potential of such predictive models, there is one major ethical consideration made about the use of genomic information in clinical practice. Several issues, related to informed consent, data ownership, and misuse of information, have to be sorted out for overall trust to be developed between healthcare providers and patients. Other concerns include equity concerning access to personalized medicine because differences in healthcare resources may lead to the exacerbation of health inequities in populations due to poor representation in predictive modeling activities.

Other important limitations lie in data quality, model interpretability, and generalizability. The predictive models are good, but only as long as the data they are trained upon. Poor and biased data result in poor predictions with enlarged current health disparities. Besides that, the sophistication of machine learning algorithms often means that models end up being a kind of "black box," such that clinicians do not know why specific predictions were made. Improvement in model interpretability is an essential corollary that will go a long way in assuring healthcare providers that they can use such tools. Generalizability remains a concern, similar to most other models. Models developed in one population will generalize poorly to others due to important differences in demographics, the prevalence of disease, treatment practices, and many underlying factors.

Directions for Future Research

In enhancing the accuracy and applicability of predictive models in personalized medicine, several areas of focus will be important in future research. First, larger and more diverse datasets are developed that will train models better reflecting the population's variability, including demographic diversity and a variety of comorbidities and treatment histories. Collaboration between academia, healthcare providers, and industry stakeholders may facilitate the sharing or pooling of data for more robust predictive models.

Of greater promise is individualized treatment planning based on real-time integration of genomic data. Using next-generation sequencing coupled with wearable health monitors, for example, researchers have been able to develop model systems that report in near real-time how patients respond to treatments. Such an approach may therefore enable timely treatment adjustments with the aim of best patient outcomes while reducing unfavorable side effects. It would, therefore, be necessary that studies focus on integration with artificial intelligence systems so that the potential for improving predictive

analytics with personalized medicine can fully change the aspects of patient care in the US healthcare system.

CONCLUSION

This research project aimed to identify a set of genetic variations or mutations that influence the individual response of a cancer patient to certain drugs. This study also aimed to develop machine learning models that can analyze a patient's genomic data to predict their likely response to different therapies. This study utilized the Genomic of Drug Sensitivity in Cancer (GDSC). The GDSC dataset is a very valued resource in therapeutic biomarker discovery in cancer research. This dataset combined drug response data with genomic profiles of cancer cell lines, enabling investigations into the relationship between genetic features and drug sensitivity. The main task associated with this dataset was to predict drug sensitivity, measured as IC50 values, from genomic features of cancer cell lines. Several accredited and proven Machine Learning algorithms were utilized in the study, particularly, Linear Regression, Ridge Regression, and SGD Regression. The most important regression model evaluation metrics deployed in a drug sensitivity prediction included the Mean Squared Error- MSE, Root Mean Squared Error- RMSE, and Mean Absolute Error- MAE. The Ridge Regression model outperformed the Linear Regression and the SGD algorithm, particularly, the Ridge Regression model captured excellently the hidden trends in the data much better compared to the other two models. Predictive analytics can significantly enhance clinical decision-making in the USA by providing health professionals with data-driven insights into the best available treatment options. As patient complexity and treatment options continue to grow, such models will help clinicians choose the most appropriate interventions for individual patients, informed by historical data on their disease course and other individual patient factors, including genetic profiling and comorbid status.

REFERENCES

1. Acanda De La Rocha, A. M., Berlow, N. E., Fader, M., Coats, E. R., Saghira, C., Espinal, P. S., ... & Azzam, D. J. (2024). Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nature Medicine, 1-11.
2. Alam, S., Hider, M. A., Al Mukaddim, A., Anonna, F. R., Hossain, M. S., khalilor Rahman, M., & Nasiruddin, M. (2024). Machine Learning Models for Predicting Thyroid Cancer Recurrence: A Comparative Analysis. Journal of Medical and Health Studies, 5(4), 113-129.
3. Alipour, S. (2024, August 13). Genomics of Drug Sensitivity in Cancer (GDSC). Kaggle. https://www.kaggle.com/datasets/samiraalipour/genomics-of-drug-sensitivity-in-cancer-gdsc
4. Al Amin, M., Liza, I. A., Hossain, S. F., Hasan, E., Haque, M. M., & Bortty, J. C. (2024). Predicting and Monitoring Anxiety and Depression: Advanced Machine Learning Techniques for Mental Health Analysis. British Journal of Nursing Studies, 4(2), 66-75.
5. Bhowmik, P. K., Miah, M. N. I., Uddin, M. K., Sizan, M. M. H., Pant, L., Islam, M. R., & Gurung, N. (2024). Advancing Heart Disease Prediction through Machine Learning: Techniques and Insights for Improved Cardiovascular Health. British Journal of Nursing Studies, 4(2), 35-50.
6. Brancato, V., Esposito, G., Coppola, L., Cavaliere, C., Mirabelli, P., Scapicchio, C., ... & Aiello, M. (2024). Standardizing digital biobanks: integrating imaging, genomic, and clinical data

for precision medicine. Journal of Translational Medicine, 22(1), 136.

7. Bortty, J. C., Bhowmik, P. K., Reza, S. A., Liza, I. A., Miah, M. N. I., Chowdhury, M. S. R., & Al Amin, M. (2024). Optimizing Lung Cancer Risk Prediction with Advanced Machine Learning Algorithms and Techniques. Journal of Medical and Health Studies, 5(4), 35-48.

8. Chafai, N., Bonizzi, L., Botti, S., & Badaoui, B. (2024). Emerging applications of machine learning in genomic medicine and healthcare. Critical Reviews in Clinical Laboratory Sciences, 61(2), 140-163.

9. Dutta, S., Sikder, R., Islam, M. R., Al Mukaddim, A., Hider, M. A., & Nasiruddin, M. (2024). Comparing the Effectiveness of Machine Learning Algorithms in Early Chronic Kidney Disease Detection. Journal of Computer Science and Technology Studies, 6(4), 77-91.

10. Fawaz, A., Ferraresi, A., & Isidoro, C. (2023). Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making. Journal of Personalized Medicine, 13(11), 1590.

11. Hider, M. A., Nasiruddin, M., & Al Mukaddim, A. (2024). Early Disease Detection through Advanced Machine Learning Techniques: A Comprehensive Analysis and Implementation in Healthcare Systems. Revista de Inteligencia Artificial en Medicina, 15(1), 1010-1042.

12. Hossain, M. S., Rahman, M. K., & Dalim, H. M. (2024). Leveraging AI for Real-Time Monitoring and Prediction of Environmental Health Hazards: Protecting Public Health in the USA. Revista de Inteligencia Artificial en Medicina, 15(1), 1117-1145.

13. Islam, M. Z., Nasiruddin, M., Dutta, S., Sikder, R., Huda, C. B., & Islam, M. R. (2024). A Comparative Assessment of Machine Learning Algorithms for Detecting and Diagnosing Breast Cancer. Journal of Computer Science and Technology Studies, 6(2), 121-135.

14. Kang, C. C., Lee, T. Y., Lim, W. F., & Yeo, W. W. Y. (2023). Opportunities and challenges of 5G network technology toward precision medicine. Clinical and Translational Science, 16(11), 2078-2094.

15. Laxmi Pant, Abdullah Al Mukaddim, Md Khalilor Rahman, Abdullah AL Sayeed, Md Sazzad Hossain, MD Tushar Khan, & Adib Ahmed. (2024). Genomic predictors of drug sensitivity in cancer: Integrating genomic data for personalized medicine in the USA. Computer Science & IT Research Journal, 5(12), 2682-2702. https://doi.org/10.51594/csitrj.v5i12.1760

16. Joshi, I., Bhrdwaj, A., Khandelwal, R., Pande, A., Agarwal, A., Srija, C. D., ... & Singh, S. K. (2023). Artificial intelligence, big data and machine learning approaches in genome-wide SNP-based prediction for precision medicine and drug discovery. In Big data analytics in chemoinformatics and bioinformatics (pp. 333-357). Elsevier.

17. Obijuru, A., Arowoogun, J. O., Onwumere, C., Odilibe, I. P., Anyanwu, E. C., & Daraojimba, A. I. (2024). Big data analytics in healthcare: a review of recent advances and potential for personalized medicine. International Medical Science Research Journal, 4(2), 170-182.

18. Rahman, A., Karmakar, M., & Debnath, P. (2023). Predictive Analytics for Healthcare: Improving Patient Outcomes in the US through Machine Learning. Revista de Inteligencia Artificial en Medicina, 14(1), 595-624.

19. Restrepo, J. C., Dueñas, D., Corredor, Z., &

Liscano, Y. (2023). Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment. Cancers, 15(13), 3474.

20. Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023). Pharmacogenomics: driving personalized medicine. Pharmacological reviews, 75(4), 789-814.

21. Tong, L., Shi, W., Isgut, M., Zhong, Y., Lais, P., Gloster, L., ... & Wang, M. D. (2023). Integrating multi-omics data with EHR for precision medicine using advanced artificial intelligence. IEEE Reviews in Biomedical Engineering.

22. Udegbe, F. C., Ebulue, O. R., Ebulue, C. C., & Ekesiobi, C. S. (2024). Precision Medicine and Genomics: A comprehensive review of IT-enabled approaches. International Medical Science Research Journal, 4(4), 509-520.

23. Wang, R. C., & Wang, Z. (2023). Precision medicine: disease subtyping and tailored treatment. Cancers, 15(15), 3837.